companydata.dkLEO FONDET
CVR: 11623336
Secondary names: LEO Pharma Forskningsfond in memoriam August Kongsted
LEO FONDET has demonstrated a significant turnaround in financial health, achieving a remarkable revenue increase from 9.96 billion DKK in 2021 to 13.50 billion DKK in 2025, alongside a profit rebound from a loss of 5.25 billion DKK in 2022 to a profit of 3.46 billion DKK in 2025. The company's equity has also strengthened, rising from 17.91 billion DKK in 2024 to 21.09 billion DKK in 2025, indicating a solid capital position. Despite previous years of losses, the current trajectory suggests a robust recovery, positioning LEO FONDET favorably within the non-financial holding companies sector. However, the volatility in profit margins raises concerns about sustainability in the long term.
AI-generated summary
Overview
Details
Contact
Purpose
Fondens primære formål er i overenstemmelse med § 1 at sikre videreførelsen af LEO Pharma A/S med dertil knyttede selskaber. Bestyrelsen kan foretage de henlæggelser, den finder rimelige, til konsolidering af fondet. Overskud herefter kan i det omfang, bestyrelsen finder det forsvarligt og eventuelt efter indstilling fra LEO Pharma A/S, anvendes til at yde støtte til forskning inden for områderne medicin, kemi og/eller farmaci.
Location
Financials
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2025 | 13.5 mia. | 3.5 mia. | 39.5 mia. | 21.1 mia. | 4121 | |
History
Ownership
Management
Directors
Board
Production units (5)
Similar companies
Companies in the same industry and area